von Renesse Janusz, Lin Mei-Chun, Ho Ping-Chih
Department of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
Department of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland; Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
Trends Cancer. 2025 May 9. doi: 10.1016/j.trecan.2025.04.008.
The pivotal role of tumor-draining lymph nodes (TDLNs) in supporting antitumor immunity and serving as sites for cancer metastasis presents a clinical challenge: eliminate tumors while preserving antitumor immune responses. In this article, we explore the initiation of tumor-specific immune responses within lymph nodes (LNs), the immunocompromised microenvironment induced by tumors within LNs, and the crucial involvement of TDLNs in immunotherapy. Additionally, we examine the clinical prospects of modifying surgical procedures or therapy sequences to enhance the efficacy of cancer treatment.
肿瘤引流淋巴结（TDLNs）在支持抗肿瘤免疫及作为癌症转移部位方面的关键作用带来了一项临床挑战：在保留抗肿瘤免疫反应的同时消除肿瘤。在本文中，我们探讨了淋巴结（LNs）内肿瘤特异性免疫反应的启动、肿瘤在LNs内诱导的免疫受损微环境以及TDLNs在免疫治疗中的关键作用。此外，我们研究了调整手术程序或治疗顺序以提高癌症治疗效果的临床前景。
